OBJECTIVES: This study aims to examine the efficacy of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) for individuals diagnosed with a depressive disorder. METHOD:Participants included 44 adults who met criteria for major depressive disorder, persistent depressive disorder, or another specified depressive disorder according to the Anxiety Disorder Interview Schedule (ADIS). These individuals represent a subset of patients from a larger clinical trial comparing the UP to single-disorder protocols (SDPs) for discrete anxiety disorders and a waitlist control (WLC) condition (Barlow et al., 2017); inclusion criteria for the parent study required participants to have a principal anxiety disorder. RESULTS: Significant reductions in depressive symptoms were observed within the UP condition across clinician-rated and self-report measures of depression from baseline to post-treatment, as well as to the 12-month follow-up assessment. Compared to the WLC group, individuals in the UP condition demonstrated significantly lower levels on our continuous, clinician-rated measure of depressive symptoms at post-treatment. There were no differences between the UP and SDP conditions on depressive symptoms at post-treatment or at the 12-month follow-up timepoint. CONCLUSIONS: In this exploratory set of analyses, the UP evidenced efficacy for reduction of depressive symptoms, adding to the growing support for its utility in treating depression.
RCT Entities:
OBJECTIVES: This study aims to examine the efficacy of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) for individuals diagnosed with a depressive disorder. METHOD:Participants included 44 adults who met criteria for major depressive disorder, persistent depressive disorder, or another specified depressive disorder according to the Anxiety Disorder Interview Schedule (ADIS). These individuals represent a subset of patients from a larger clinical trial comparing the UP to single-disorder protocols (SDPs) for discrete anxiety disorders and a waitlist control (WLC) condition (Barlow et al., 2017); inclusion criteria for the parent study required participants to have a principal anxiety disorder. RESULTS: Significant reductions in depressive symptoms were observed within the UP condition across clinician-rated and self-report measures of depression from baseline to post-treatment, as well as to the 12-month follow-up assessment. Compared to the WLC group, individuals in the UP condition demonstrated significantly lower levels on our continuous, clinician-rated measure of depressive symptoms at post-treatment. There were no differences between the UP and SDP conditions on depressive symptoms at post-treatment or at the 12-month follow-up timepoint. CONCLUSIONS: In this exploratory set of analyses, the UP evidenced efficacy for reduction of depressive symptoms, adding to the growing support for its utility in treating depression.
Authors: Tonelle E Handley; Kerry J Inder; Brian J Kelly; John R Attia; Terry J Lewin; Michael N Fitzgerald; Frances J Kay-Lambkin Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2011-10-12 Impact factor: 4.328
Authors: Todd J Farchione; Christopher P Fairholme; Kristen K Ellard; Christina L Boisseau; Johanna Thompson-Hollands; Jenna R Carl; Matthew W Gallagher; David H Barlow Journal: Behav Ther Date: 2012-01-18
Authors: David H Barlow; Todd J Farchione; Jacqueline R Bullis; Matthew W Gallagher; Heather Murray-Latin; Shannon Sauer-Zavala; Kate H Bentley; Johanna Thompson-Hollands; Laren R Conklin; James F Boswell; Amantia Ametaj; Jenna R Carl; Hannah T Boettcher; Clair Cassiello-Robbins Journal: JAMA Psychiatry Date: 2017-09-01 Impact factor: 21.596
Authors: David Watson; Holly F Levin-Aspenson; Monika A Waszczuk; Christopher C Conway; Tim Dalgleish; Michael N Dretsch; Nicholas R Eaton; Miriam K Forbes; Kelsie T Forbush; Kelsey A Hobbs; Giorgia Michelini; Brady D Nelson; Martin Sellbom; Tim Slade; Susan C South; Matthew Sunderland; Irwin Waldman; Michael Witthöft; Aidan G C Wright; Roman Kotov; Robert F Krueger Journal: World Psychiatry Date: 2022-02 Impact factor: 79.683
Authors: Shannon Sauer-Zavala; Jay C Fournier; Stephanie Jarvi Steele; Brittany K Woods; Mengxing Wang; Todd J Farchione; David H Barlow Journal: Psychol Med Date: 2020-04-21 Impact factor: 7.723